Liposome destabilization induced by the HIV-1 fusion peptide Effect of a single amino acid substitution  by Pereira, Francisca B. et al.
FEBS 15329 FEBS Letters 362 (1995) 243-246 
Liposome destabilization induced by the HIV-1 fusion peptide 
Effect of a single amino acid substitution 
Francisca B. Pereira, F61ix M. Gofii, Jos6 L. Nieva* 
Department ofBiochernistry and Molecular Biology, University of the Basque Country, PO Box 644, 48080 Bilbao, Spain 
Received 13 February 1995; revised version received 2 March 1995 
Abstract The 23-residue synthetic peptide representing the N- 
terminus of HIV-1 gp41 is known to induce either leakage or 
fusion of lipid vesicles depending on the experimental conditions. 
In this paper we report that a polar amino acid substitution V--~ E 
at position 2, known to block gp41 activity in vivo, makes the 
peptide unable to destabilize and/or fuse membranes. Moreover 
this variant, unlike the parent peptide, is never found in the 
membrane-associated i~ conformation. 
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1. Introduction 
It has been proposed that a pivotal event during the HIV-1 
fusion mediated by the envelope protein gp 120/41 would be the 
exposure of a putative fusogenic sequence, a conserved hydro- 
phobic segment of about 25 amino acids located at the N- 
terminus of gp41 [1]. The interaction of this hydrophobic 
stretch or 'fusion peptide' [2] with the target membrane could 
induce some kind of molecular destabilization essential for the 
completion of the process. The involvement of the N-terminus 
of gp41 in HIV fusion in vivo has been demonstrated bymuta- 
tional analysis. Syncytium formation in transfected cell systems 
is enhanced by mutations within this sequence that increase its 
hydrophobicity [3], while substitutions that increase the charge 
can block the process [4]. More recently, Freed et al. [5] have 
reported that a single polar substitution V~E at position 2, 
known to block syncytium formation [4], leads to a mutant 
envelope glycoprotein ( amed 41.2 after the mutant) that com- 
pletely interferes with syncytium formation and infection medi- 
ated by the wild-type fusion protein. The interfering effect is 
detected even in the presence of excess wild-type glycoprotein, 
suggesting that a higher-order protein complex must be in- 
volved in membrane fusion. 
With the aim of testing the membrane destabilizing effects of 
the HIV-I fusion peptide, several studies have been conducted 
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droxyethyl)-piperazine-N'-2-ethanesulfo nic acid; HIV, human immu- 
nodeficiency virus; HIVw~, synthetic N-terminal sequence (23 aa) of 
HIV-1 gp41; HIVE: synthetic N-terminal sequence (23 aa) of HIV-1 
gp41 bearing the V--~E substitution at position 2; LUV, large unilamel- 
lar vesicles; N-NBD-PE, N-(7-nitrobenz-2-oxa- 1,3 diazol-4- 
yl)phosphatidylethanolamine ; PC, phosphatidylcholine; PE,phophati- 
dylethanolamine; POPG, 1-palmitoyl-2-oleoylphosphatidylglycerol; N- 
Rh-PE, N-(lissamine rhodamine B sulfonyl)phosphatidylethanolamine. 
in model membranes using synthetic peptides representing this 
sequence. Rafalski et al. [6] showed destabilization of POPG 
liposomes and membrane mixing of small sonicated vesicles. 
Slepushkin et al. [7] showed the ability of a family of gp41 
peptides to cause increased conductance of planar lipid bilay- 
ers, liposome lysis and lipid mixing. The HIV-1 fusion peptide 
has been shown to induce lysis of human erythrocytes and 
CD4 ÷ lymphocytes [8]. A 16-amino acid peptide has been re- 
ported to induce lipid mixing and leakage of contents in PC: PE 
containing vesicles [9]. 
In an attempt o establish a relationship between peptide 
membrane activity and structure, we have recently carried out 
a study in a liposomal system using a 23-residue synthetic pep- 
tide (HIVarg) derived from the LAV~a strain of HIV-1 [10]. The 
peptide alone could not aggregate negatively charged large uni- 
lamellar POPG vesicles. When Ca 2+ or Mg 2÷ were first added 
to the POPG LUV, inducing aggregation but not fusion of the 
vesicles, the subsequent addition of the peptide initiated vesicle 
fusion. HIVarg also induced leakage of small molecules from 
the vesicles by forming membrane pores but only in the absence 
of cations. We observed that, for HIVarg and POPG liposomes, 
pore formation and membrane fusion required different pep- 
tide conformations represented by an c~-helix and a t-structure, 
respectively [10]. 
Here, using a similar approach, we have evaluated the effect 
of the V--*E substitution at position 2 on both membrane activ- 
ity and conformation of a related HIV-1 fusion peptide. The 
former substitution was selected in view of the already men- 
tioned dramatic effects produced on gp41 activity in vivo [4,5]. 
2. Materials and methods 
2.1. Materials 
1-Palmitoyl-2-oleoylphosphatidylglycerol (POPG) and the fluores- 
cent probes, N-(7-nitrobenz-2-oxa-l,3-diazol-4-yl)phosphatidyletha- 
nolamine (N-NBD-PE) and N-(lissamine rhodamine B sul- 
fonyl)phosphatidylethanolamine (N-Rh-PE) were purchased from 
Avanti Polar Lipids (Birmingham, AL, USA). 8-Aminonaphta- 
lene-l,3,6-trisulfonic acid sodium salt (ANTS) and p-xylene- 
bis(pyridinium)bromide (DPX) were from Molecular Probes (Junc- 
tion City, OR, USA). Triton X-100 was obtained from Sigma (St. 
Louis, MO, USA). Fluoraldehyde reagent was from Pierce (Rockford, 
IL, USA). All other reagents were of analytical grade. 
2.2. Peptide synthesis 
The sequences, AVGIGALFLGFLGAAGSTMGAAS (HIVw,) and 
AEGIGALFLGFLGAAGSTMGAAS (HIVE2) representing the N- 
terminus of the HIV gp41 (HXB-2 viral clone) and its 41.2 mutant [4,5], 
respectively, were synthesized as their C-terminal carboxamides by 
Dr. T. Saermark (EC Concerted Action Programme) as previously 
described [11]. Purification was carried out by reverse-phase HPLC 
(estimated homogeneity >90%). Final amino acid analysis confirmed 
the correct composition. Peptide stock solutions were prepared in 
DMSO (spectroscopic grade). 
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2.3. Vesicle preparation 
Large unilamellar vesicles (LUV) of POPG were prepared according 
to the extrusion method of Hope et al. [12] as previously described [10]. 
2.4. Fluorimetric assays Jbr vesicle fusion and leakage 
All fluorescence measurements were conducted in thermostatically 
controlled cuvettes using a Perkin-Elmer LS50-B spectrofluorimeter. 
The medium in the cuvettes was continuously stirred to allow the rapid 
mixing of peptides and vesicles. 
Membrane fusion was demonstrated as the mixing of the lipidic 
components of the vesicles. Lipid mixing was monitored using the 
resonance energy transfer assay, described by Struck et al. [13]. Vesicles 
containing 0.6 mol% of N-NBD-PE and N-Rh-PE were mixed with 
unlabeled vesicles in a 1 : 4 ratio. The NBD emission was monitored at 
530 nm with the excitation wavelength set at 465 nm. A cutofffilter at 
515 nm was used between the sample and the emission monochromator 
to avoid scattering interferences. The fluorescence scale was calibrated 
such that the zero level corresponded tothe initial residual fluorescence 
of the labeled vesicles, and the 100% value to the complete mixing of 
all the lipids in the system. The latter value was set by the fluorescence 
intensity of vesicles, labeled with 0.15 mol% each of the fluorophores, 
at the same total lipid concentration as in the fusion assay. 
Release of vesicular contents to the medium was monitored as in [10], 
by the ANTS/DPX assay [14]. LUV containing 12.5 mM ANTS, 45 
mM DPX, 20 mM NaCI and 5 mM HEPES, were obtained by separat- 
ing the unencapsulated material by gel-filtration i  a Sephadex G-75 
column eluted with 5 mM HEPES, 100 mM NaC1 (pH 7.4). Osmolar- 
ities were adjusted to 200 mosm. Fluorescence measurements were 
performed by setting the ANTS emission at 520 nm and the excitation 
at 355 nm. A cutoff ilter (470 nm) was placed between the sample and 
the emission monochromator. The 0% leakage corresponded to the 
fluorescence of the vesicles at time zero; 100% leakage was the fluores- 
cence value obtained after addition of Triton X-100 (0.5% v/v). 
2.5. Peptide binding to vesicles 
Peptide binding to vesicles was estimated by flotation analysis of the 
peptide-liposome complexes in D20 buffer (5 mM HEPES, 100 mM 
NaCI, pH 7.4). Peptide dissolved in DMSO was added to 1 ml POPG 
LUV (1 mM) prepared in D20 buffer (peptide-to-lipid ratio, 1 : 100). 
After 30 min incubation at room temperature, centrifugation of the 
peptide-lipid complexes in a Beckman Optima TLX ultracentrifuge in 
a TL100 rotor (627,000xg, 120 min) gave rise to a homogeneous band 
of vesicles floating on top of the DzO buffer. The tubes were fraction- 
ated from the top and peptide distribution was subsequently quanti- 
tated by the fluoraldehyde assay following the instructions of the man- 
ufacturer. Vesicle distribution was determined after phosphate analysis 
[15] of the same fractions. 
2.6. Infrared spectroscopy 
Measurements were essentially conducted as in [10] on peptide lipid 
complexes obtained in D20 buffer following the above binding proto- 
col. Infrared spectra were recorded in a Nicolet 520 spectrometer 
equipped with a DTGS detector. Samples, containing =4 mg peptide/ 
ml, were placed between two CaF2 windows separated by 50 ~m spac- 
ers. 200 sample scans and 200 reference scans were taken for each 
spectrum, using a shuttle device. Spectra data were transferred to a 
personal computer where solvent subtraction and band-position deter- 
minations were performed as previously reported [16]. 
3. Results 
In Fig. 1, the effects of HIVw, and HIVE2 on POPG LUV 
stability are comparatively shown. The peptides in this example 
were added at a relatively high dose (peptide-to-lipid, 1 : 15) in 
order to rule out the existence of different hreshold peptide-to- 
lipid ratios for the induction of destabilization. Higher doses 
were likely to induce destabilization via unspecific mechanisms. 
As shown in panel A, HIVwt induced extensive leakage of 
ANTS from the vesicles (75% after 90 s) whereas the addition 
of HIVE2 resulted in a much smaller release (15% after 90 s). 
Thus the substitution severely affected the ability of the peptide 
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Fig. 1. Effect of V---~E substitution on HIV-1 fusion peptide-induced 
POPG LUV destabilization. HIVwt (curves a) and HIVE2 (curves b) 
were added to vesicle suspensions and their effects on vesicle stability 
compared. Vesicle concentration was 50 pM. Peptides were added at 
time -- 30 s (peptide-to-lipid ratio of 1: 15). Fluorescence was recorded 
continuously. (A) Kinetics of leakage of ANTS/DPX. (B) Kinetics of 
membrane lipid mixing (resonance energy transfer assay). The medium 
contained 5 mM Ca 2+ in this case. 
to disrupt the permeability barrier of the POPG vesicles. The 
results in panel B demonstrate hat HIVE2 was unable to induce 
mixing of the membrane lipids in the presence of 5 mM Ca 2+ 
as compared to HIVwt. 90 s after addition of HIVE2, virtually 
no membrane mixing was detected by the resonance nergy 
transfer assay whereas HIVwt induced the mixing of 50% of the 
vesicular lipids. 
We also checked in the POPG LUV system the ability of 
HIVE2 to interfere with HIVwt-induced leakage and fusion (data 
not shown). Several HIVwt-to-HIVE2 ratios ranging from 1:1 
to 1 : 10 and different protocols were tested. Addition of pre- 
mixed HIVwt and HIVE2 displayed the same effects as HIVwt 
alone, and pre-addition of HIVE2 to the vesicles did not affect 
either leakage or membrane mixing induced by HIVwt. HIVEz 
addition at any time after the onset of HIVw,-induced estabil- 
ization also did not affect the course of the kinetics in either 
case. We thus conclude that HIVE2 was unable to interfere with 
the activity of HIVwt. 
The binding data in Fig. 2 demonstrate that the differences 
detected in the previous experiments were not due to differences 
in the vesicle-binding ability of the peptides. Both in the absence 
(panels A and C) and in the presence (panels B and D) of 5 mM 
Ca 2+, the distribution patterns of HIVwt and HIVE2 were very 
similar after flotation. Therefore we can assume the existence 
of a comparable amount of both variants associated to vesicles. 
The data also suggest a higher amount of peptide associated to 
the top fraction of vesicles in the presence of the cation. Under 
the latter conditions, HIVwl induced vesicle fusion. 
Infrared analysis of the peptide-lipid complexes floating in 
D20 buffer corroborated the earlier binding data. The spectra 
in Fig. 3 displayed an intense band centered at 1734/1735 cm -1, 
corresponding to the CO0-  stretching vibration of the phos- 
pholipid ester bonds, together with bands in the conformation- 
sensitive amide I region corresponding to the peptides. The 
relative intensities of the peptide and lipid bands indicated a 
comparable degree of binding for both peptides. Conversely, 
these bands suggested the existence of a distinct conformational 
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behaviour for each peptide. In the absence of Ca 2+ (panel A) 
both HIVw, (curve a) and HIVE2 (curve b) spectra displayed a
main band centered at 1657 cm -~, indicating a preferential 
a-helical conformation adopted by both peptides in the mem- 
brane. However, in the presence of Ca 2+ (panel B), spectrum 
a included a conspicuous band, centered at 1626 cm -~, indica- 
tive of the presence of a population of peptide backbones in 
fl-conformation. This band was absent in spectrum b. We con- 
cluded that HIVw,, but not HIVE2, could adopt a fl-conforma- 
tion in the membrane under conditions allowing fusion. 
4. Discussion 
Taken together, the results described above demonstrate hat 
a single substitution in HIVw, that did not affect its binding 
capacity, brought about dramatic effects as to its ability to 
destabilize membranes and inhibited its adoption of a fl-confor- 
mation in the membrane under conditions allowing fusion. 
First we found that, in contrast to HIVwt, HIVE2 was unable to 
promote extensive leakage of vesicle contents (Fig. 1). Such 
inability can not be easily interpreted in terms of structure since 
both HIV,, t and HIVE2 showed similar a-helix contents when 
associated to vesicles (Fig. 3). Clearly additional requirements, 
e.g. the formation of peptide aggregates or pores [10], must be 
met in order to effectively disrupt the permeability barrier of 
the vesicles. Nevertheless, the absence of HIVE2-induced vesicle 
fusion can be correlated with its inability to adopt in the mem- 
brane the fl structure adopted by the wild-type peptide under 
conditions allowing this process (i.e. in the presence of 5 mM 
Ca2+). The lack of liposome fusion induced by another HIV- 
derived peptide carrying the same mutation has been recently 
observed as well (J. Wilschut, L. Yang, S.Q. Nie and K.C. Lin, 
submitted for publication). Given the short length of the pep- 
tide and the position of the substitution, it appears again that 
peptide peptide interactions to form higher order complexes, 
in which the glutamate residue could cause extensive conforma- 
tional disruption, might be involved in membrane destabiliza- 
tion. Whereas on isolated vesicles the peptides in those com- 
plexes are probably assembled forming pores, they must form 
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Fig. 2. Binding of HIVwt (A,B) and HIVE2 (C,D) to POPG LUV in 
absence (A,C) and in presence (B,D) of 5 mM Ca 2+. Attachment ofthe 
peptides to the liposomes was assessed by co-flotation analysis in D20 
buffer (5mM HEPES, 100 mM NaCI, pH 7.4). Fraction 1 corresponds 
to the top of the tube. Filled circles correspond topercentage ofthe total 
peptide subjected to flotation, and open circles to the total ipid. More 
than 90% of the total peptide was collected in the bottom fraction in 
the absence of vesicles (data not shown). 
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Fig. 3. Infrared spectra of HIVw, (curves a) and HIVE2 (curves b) bound 
to POPG vesicles. The peptides (peptide-to-lipid ratio 1:100) were 
added to LUV (1 mM) under the experimental conditions used in the 
fusion and leakage assays (see section 2). (A) In the absence of 5 mM 
Ca 2+. (B) In the presence of 5 mM Ca 2+. 
some different kind of structures when cations pre-aggregate 
the membranes [10]. 
The situation in vivo is qualitatively different. It has been 
suggested that the gpdl external domain is responsible for sur- 
face oligomerization of the HIV-I envelope protein [17]. Thus, 
the interfering effect on infectivity and fusion exerted by the 
41.2 mutant could be explained in terms of pre-existing protein 
complexes that contain mutant monomers [5]. Our results ug- 
gest that those mutant monomers would bear a defective fusion 
peptide which lacks affinity towards its companions and are 
unable to induce membrane destabilization. We speculate here 
that the presence of those defective fusion peptides could be 
enough to distort the correct architecture of the fusion sites 
built by the otherwise functional protein complexes. This could 
also explain the dramatic effect displayed by this single substi- 
tution on gpdl activity in vivo. 
One interesting finding in this study is that the active peptide, 
in contrast to the inactive one, was able to adopt a fl structure 
in the membrane. Initial studies on fusion peptides have been 
conducted under the prevailing assumption of the s-helix repre- 
senting the characteristic fusogenic onformation of these pep- 
tides [6,18-20]. However, this notion has been questioned as a 
general rule by Gallaher et al. [21] and recent reports favor fl 
structures as the putative fusogenic onformations of certain 
fusion peptides in vesicular systems [10,22,23]. It appears that 
in those systems, factors like the use of appropiate vesicles as 
LUV to measure peptide-induced membrane destabilization 
(for a discussion on this issue see [24]) and the determination 
of peptide conformation under conditions comparable to those 
used to measure membrane fusion and destabilization, can 
become extremely important in order to establish the correct 
function-structure r lationship [10,23]. The fact that a single 
substitution abolishing fusion leads to the absence of the fl 
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structure while keeping intact he ability of the peptide to adopt 
the s-helix conformation, argues in favor of the former struc- 
ture as representing a crucial element for the activation of 
fusion in our system. To our knowledge, this is the first time 
that a substitution i the HIV-I fusion peptide, known to block 
gp41 fusion activity, is related to the loss of a functional confor- 
mation. Moreover, our findings highlight he relevance that the 
adoption by the fusion peptide of such a structure could have 
in vivo for HIV-1 fusion. 
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